Facilitating the medical management of benign prostatic hyperplasia in primary care

BJU International

Volumn 104, Issue 6, 2009, Pages 751-753

  Kirby, Roger ^a   Kirby, Michael ^a   Fitzpatrick, John ^b  

^a Prostate Centre   (United Kingdom)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER SCREENING; DIZZINESS; FATIGUE; HUMAN; NOTE; PATIENT REFERRAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SEXUAL DYSFUNCTION;

FAMILY PRACTICE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; PROSTATIC HYPERPLASIA;

EID: 69249135489     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08824.x     Document Type: Note

References (15)

1. Speakman MJ, Kirby RS, Joyce A et al. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004 93 : 985 990
2. Abrams P, Chapple C, Khoury S et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009 181 : 1779 1787
3. Roehrborn CG, Boyle P, Bergner D et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999 54 : 662 669
4. Schröder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009 360 : 1320
5. Arlen PM, Bianco F Dahut WL et al. Prostate-Specific Antigen Working Group's Guidelines on PSA Doubling Time. J Urol 2008 179 : 2181 2186
6. Kirby RS, Fitzpatrick JM, Irani J. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU Int 2009 103 : 441 445
7. Kaplan S. Current role of alpha-blockers in the treatment of benign prostatic hyperplasia. BJU Int 2008 102 (Suppl. 2 3 7
8. Roehrborn CG, Marks LS, Fenter T et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004 63 : 709 715
9. Barkin J, Guimarães M, Jacobi G et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5a-reductase inhibitor dutasteride. Eur Urol 2003 44 : 461 466
10. Roehrborn C, Siami P, Barkin J et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008 179 : 616 621
11. NICE. Guideline 87. Type 2 Diabetes-Newer Agents (Partial Update of CG66). National Institute of Clinical Excellence, May 2009.
12. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 349 : 2387 2398
13. Gilling P. Holmium laser enucleation of the prostate (HoLEP). BJU Int 2008 101 : 131 142 (Pubitemid 350233573)
14. Kirby RS, Fitzpatrick JM, Kirby MG, Fitzpatrick A. Shared Care for Prostatic Diseases. Oxford : Isis Medical Media, 1995
15. Tanguay S, Awde M, Brock G et al. Diagnosis and management of benign prostatic hyperplasia in primary care. Can Urol Assoc J 2009 3 (Suppl. 2 S92 100